Agios Pharmaceuticals
AGIO
207 hedge funds and large institutions have $2.58B invested in Agios Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 78 increasing their positions, 68 reducing their positions, and 24 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 68
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
3% more capital invested
Capital invested by funds: $2.51B → $2.58B (+$75.3M)
1% more funds holding
Funds holding: 205 → 207 (+2)
0.28% less ownership
Funds ownership: 102.43% → 102.15% (-0.28%)
15% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $21.1M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$45.5M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$34.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.83M |
| 4 |
CCM
Cutter Capital Management
New York
|
+$8.48M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$7.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$28.8M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$19.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$15.7M |
| 4 |
Morgan Stanley
New York
|
-$11.2M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$10.7M |
AGIO Hedge Fund Activity: Q3 2024 in Review
207 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2024, worth a combined $2.58B — up 3% from $2.51B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AGIO positions and 24 closed out — a net gain of 2 holders — while 78 added to existing stakes and 68 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $45.5M. The largest seller was Dimensional Fund Advisors, cutting an estimated $28.8M.
- 207 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2024, up from 205 in Q2 2024.
- Funds reported $2.58B of Agios Pharmaceuticals stock for Q3 2024, up 3% quarter-over-quarter.
- 26 funds opened new Agios Pharmaceuticals positions in Q3 2024 and 24 closed out, a net change of +2 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2024 was Polar Capital Holdings, an estimated $45.5M added.
- The largest Agios Pharmaceuticals seller in Q3 2024 was Dimensional Fund Advisors, an estimated $28.8M sold.
Based on aggregated 13F filings for Q3 2024.